Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
Results from ongoing, dose-escalation alloSHRINK Phase 1 trial demonstrate absence of graft-versus-host disease for first-in-class, non-gene edited allogeneic CAR-T candidate, CYAD-101, when...
-
MONT-SAINT-GUIBERT, Belgium, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET MONT-SAINT-GUIBERT, Belgium, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq:...
-
MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 ...
-
MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...